Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Schmid

Showing results (681-690 of 731) with videos related to

Pageof 74
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patientsP F Conte, M V Dieci, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA studyP Schmid, H-C Wang, F Lynce, et al.
Allergy|September 2, 2005
Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN networkL Heinzerling, A J Frew, C Bindslev-Jensen, et al.
Virchows Archiv : an International Journal of Pathology|May 5, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trialsM Graeser, O Gluz, C Zu Eulenburg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2023
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)S Loibl, H A Azim, T Bachelot, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Plos One|January 6, 2025
Expanding first-line options for depression: Protocol of a pragmatic comparative effectiveness trial of yoga vs. behavioral activation (the COMPARE study)Louisa G Sylvia, Andrew M Busch, Dustin J Rabideau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 5, 2021
Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysisSofia Spampinato, Lars U Fokdal, Richard Pötter, et al.
Pageof 74

Showing results (681-690 of 731) with videos related to

Sort By:
Pageof 74
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
A-BRAVE trial: a Phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patientsP F Conte, M V Dieci, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA studyP Schmid, H-C Wang, F Lynce, et al.
Allergy|September 2, 2005
Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN networkL Heinzerling, A J Frew, C Bindslev-Jensen, et al.
Virchows Archiv : an International Journal of Pathology|May 5, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trialsM Graeser, O Gluz, C Zu Eulenburg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2023
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)S Loibl, H A Azim, T Bachelot, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Plos One|January 6, 2025
Expanding first-line options for depression: Protocol of a pragmatic comparative effectiveness trial of yoga vs. behavioral activation (the COMPARE study)Louisa G Sylvia, Andrew M Busch, Dustin J Rabideau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 5, 2021
Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysisSofia Spampinato, Lars U Fokdal, Richard Pötter, et al.
Pageof 74